Activating gene expression in mammalian cells with promoter-targeted duplex RNAs

被引:398
作者
Janowski, Bethany A. [1 ]
Younger, Scott T.
Hardy, Daniel B.
Ram, Rosalyn
Huffman, Kenneth E.
Corey, David R.
机构
[1] Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA
[2] Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA
[3] Univ Texas, SW Med Ctr, Dept Obstet & Gynecol, Dallas, TX 75390 USA
关键词
D O I
10.1038/nchembio860
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The ability to selectively activate or inhibit gene expression is fundamental to understanding complex cellular systems and developing therapeutics. Recent studies have demonstrated that duplex RNAs complementary to promoters within chromosomal DNA are potent gene silencing agents in mammalian cells. Here we report that chromosome-targeted RNAs also activate gene expression. We have identified multiple duplex RNAs complementary to the progesterone receptor ( PR) promoter that increase expression of PR protein and RNA after transfection into cultured T47D or MCF7 human breast cancer cells. Upregulation of PR protein reduced expression of the downstream gene encoding cyclooygenase 2 but did not change concentrations of estrogen receptor, which demonstrates that activating RNAs can predictably manipulate physiologically relevant cellular pathways. Activation decreased over time and was sequence specific. Chromatin immunoprecipitation assays indicated that activation is accompanied by reduced acetylation at histones H3K9 and H3K14 and by increased di- and trimethylation at histone H3K4. These data show that, like proteins, hormones and small molecules, small duplex RNAs interact at promoters and can activate or repress gene expression.
引用
收藏
页码:166 / 173
页数:8
相关论文
共 44 条
  • [1] PROGESTIN INHIBITION OF PROGESTERONE-RECEPTOR GENE-EXPRESSION IN HUMAN-BREAST CANCER-CELLS
    ALEXANDER, IE
    CLARKE, CL
    SHINE, J
    SUTHERLAND, RL
    [J]. MOLECULAR ENDOCRINOLOGY, 1989, 3 (09) : 1377 - 1386
  • [2] Design of artificial transcriptional activators with rigid poly-L-proline linkers
    Arora, PS
    Ansari, AZ
    Best, TP
    Ptashne, M
    Dervan, PB
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2002, 124 (44) : 13067 - 13071
  • [3] Badia E, 2000, CANCER RES, V60, P4130
  • [4] 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets
    Birmingham, A
    Anderson, EM
    Reynolds, A
    Ilsley-Tyree, D
    Leake, D
    Fedorov, Y
    Baskerville, S
    Maksimova, E
    Robinson, K
    Karpilow, J
    Marshall, WS
    Khvorova, A
    [J]. NATURE METHODS, 2006, 3 (03) : 199 - 204
  • [5] Novel antisense and peptide nucleic acid strategies for controlling gene expression
    Braasch, DA
    Corey, DR
    [J]. BIOCHEMISTRY, 2002, 41 (14) : 4503 - 4510
  • [6] Dynamic chromatin boundaries delineate a latency control region of Epstein-Barr virus
    Chau, CM
    Lieberman, PM
    [J]. JOURNAL OF VIROLOGY, 2004, 78 (22) : 12308 - 12319
  • [7] REGULATION OF PROGESTERONE-RECEPTOR GENE-EXPRESSION IN MCF-7 BREAST-CANCER CELLS - A COMPARISON OF THE EFFECTS OF CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE, ESTRADIOL, INSULIN-LIKE GROWTH FACTOR-I, AND SERUM FACTORS
    CHO, HS
    ARONICA, SM
    KATZENELLENBOGEN, BS
    [J]. ENDOCRINOLOGY, 1994, 134 (02) : 658 - 664
  • [8] Progesterone receptors in mammary gland development and tumorigenesis
    Conneely, OM
    Jericevic, BM
    Lydon, JP
    [J]. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2003, 8 (02) : 205 - 214
  • [9] Regulating mammalian transcription with RNA
    Corey, DR
    [J]. TRENDS IN BIOCHEMICAL SCIENCES, 2005, 30 (12) : 655 - 658
  • [10] The silent treatment: siRNAs as small molecule drugs
    Dykxhoorn, DM
    Palliser, D
    Lieberman, J
    [J]. GENE THERAPY, 2006, 13 (06) : 541 - 552